Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy

Scandinavian Journal of Gastroenterology
F LerangT Tønnesen

Abstract

In this study we compared the cure rates of two clarithromycin-based regimens in patients in whom anti-Helicobacter pylori therapy had previously failed. Thirty-three patients were randomized to receive either regimen OAC (20 mg omeprazole, 750 mg amoxicillin, and 250 mg clarithromycin) or BTC (240 mg bismuth subcitrate, 750 mg oxytetracycline, and 250 mg clarithromycin), all twice daily for 10 days. A further 28 patients were all treated with OAC. Previously failed therapy included combinations of bismuth (B), omeprazole (O), tetracycline (T), metronidazole (M), amoxicillin (A), or clarithromycin (C) in BTM (n = 48), OAM (n = 13), OA (n = 7), OCM (n = 2), or BCM (n = 1). H. pylori infection was confirmed by culture of biopsy specimens, and antimicrobial susceptibility testing was performed with the E test. H. pylori infection was cured in all patients (n = 18) with OAC and in 8 patients (53%) with BTC (P = 0.001) in the randomized group and in 27 patients (96%) receiving OAC in the open-label group. Ten-day OAC is highly effective and superior to BTC in patients in whom metronidazole-based treatment has previously failed.

References

Feb 1, 1995·Alimentary Pharmacology & Therapeutics·G D BellC Brown
Jun 1, 1996·Alimentary Pharmacology & Therapeutics·J C DelchierJ P Idström
Mar 1, 1996·Helicobacter·R W van der HulstG N Tytgat

❮ Previous
Next ❯

Citations

Nov 2, 2006·Digestive Diseases and Sciences·Jacob YahavHaim Shmuely
Mar 12, 2003·Current Treatment Options in Gastroenterology·Javier P. Gisbert, José María Pajares
Feb 20, 2004·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·J P GisbertJ M Pajares
Oct 22, 2003·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·F ParenteG Bianchi Porro
May 29, 2002·Alimentary Pharmacology & Therapeutics·J P Gisbert, J M Pajares
Apr 27, 2012·Gastroenterology Research and Practice·Javier P Gisbert
Sep 23, 2008·World Journal of Gastroenterology : WJG·Javier P Gisbert
May 9, 2008·Expert Opinion on Drug Safety·Avelyn KwokRupert Wl Leong
Mar 5, 2011·Gastroenterología y hepatología·Javier P Gisbert
Dec 25, 2010·Therapeutic Advances in Gastroenterology·Javier P Gisbert
May 16, 2006·Digestive Diseases·Francesco Di MarioCarmelo Scarpignato
Jul 18, 2014·World Journal of Gastrointestinal Endoscopy·Teresa GarridoFauze Maluf-Filho
Oct 16, 1999·Scandinavian Journal of Gastroenterology·S Olafsson, A Berstad
Jan 14, 2005·European Journal of Gastroenterology & Hepatology·Perttu Et ArkkilaMartti Färkkilä
Nov 4, 2000·Scandinavian Journal of Gastroenterology·K SeppäläT A Miettinen
Aug 26, 1998·Scandinavian Journal of Gastroenterology·F LerangA Bjørneklett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.